Key facts for DRG 816
- FY2027 relative weight
- 0.7381
- Higher than 7% of all MS-DRGs
- Change vs FY2026
- +16.8%
- FY2026 weight 0.6320
- Geometric mean LOS
- 2.1 days
- Arithmetic mean 2.6 days
- MDC
- 16
- Diseases and Disorders of Blood, Blood Forming Organs and Immunologic Disorders
- Severity level
- without CC or MCC
- National unadjusted operating payment
- $5,054.51
- Weight × $6,848.00 FY2027 standardized amount; capital adds $398.54
- Transfer policy
- Not a transfer DRG
TL;DR
MS-DRG 816 is a medical group in MDC 16 (Diseases and Disorders of Blood, Blood Forming Organs and Immunologic Disorders), at the lowest of three severity levels in its family. CMS assigns it a FY2027 relative weight of 0.7381 with a geometric mean length of stay of 2.1 days and an arithmetic mean of 2.6. Its weight moved up 16.8% from FY2026 (0.6320). That weight is higher than 7% of all MS-DRGs. Its weight sits 64.4% below DRG 814 (with MCC, 2.0729) and 29.3% below DRG 815 (with CC, 1.0444). The v44 Definitions Manual assigns it through 137 principal diagnosis codes.
What changed from FY2026 to FY2027
CMS recalibrates every MS-DRG weight annually from the prior year's MedPAR claims. For DRG 816 the FY2027 relative weight is 0.7381 against 0.6320 in FY2026, a rise of 16.79%, which exceeds the 2% threshold worth re-checking in contract models.
| Metric | FY2026 | FY2027 | Change |
|---|---|---|---|
| Relative weight | 0.6320 | 0.7381 | +0.1061 |
| Geometric mean LOS (days) | 2.0 | 2.1 | +0.1 |
| Arithmetic mean LOS (days) | 2.3 | 2.6 | +0.3 |
DRG 816 is one of the 25 largest weight increases for FY2027; the FY2027 weight-change report ranks it against the other movers.
CC and MCC family
DRG 816 shares its base definition with 2 other MS-DRGs split by severity. The family's weights span 0.7381 to 2.0729, a 2.81× spread, which is the payment effect of documenting qualifying complications and comorbidities.
| DRG | Title | FY2027 weight | GMLOS | National operating payment |
|---|---|---|---|---|
| 814 | Reticuloendothelial and Immunity Disorders with MCC | 2.0729 | 4.8 | $14,195.22 |
| 815 | Reticuloendothelial and Immunity Disorders with CC | 1.0444 | 3.0 | $7,152.05 |
| 816 | Reticuloendothelial and Immunity Disorders without CC/MCC | 0.7381 | 2.1 | $5,054.51 |
At the national rate, documenting the family's top severity level (DRG 814, $14,195.22) instead of its base level (DRG 816, $5,054.51) changes the operating payment by $9,140.71, the amount at stake when a qualifying secondary diagnosis goes undocumented. The figures are national operating amounts before the hospital-specific adjustments described below.
National unadjusted payment for DRG 816
Multiplying the FY2027 relative weight (0.7381) by the national rates in IPPS Tables 1A and 1D, as corrected by notice CMS-1849-CN3, gives the base amounts below. Across the CC/MCC family the operating amount spans $9,140.71.
| Component | National rate | DRG 816 |
|---|---|---|
| Operating (labor and nonlabor share) | $4,519.68 + $2,328.32 = $6,848.00 | $5,054.51 |
| Capital (federal rate) | $539.95 | $398.54 |
| Operating plus capital | $5,453.05 |
These are national, unadjusted figures, not what a given hospital is paid. The labor share is multiplied by the hospital's wage index (Table 1A applies when the wage index is above 1.0 and Table 1B otherwise), and teaching (IME), disproportionate share (DSH), outlier, transfer and new-technology add-on rules then change the amount for each stay. Use the figures to compare groups and to size a documentation finding, not to forecast a remittance; the DRG payment calculator applies a hospital's own wage index and teaching and DSH factors to DRG 816.
Risk-adjusting diagnoses in this DRG
Appendix B of the v44 Definitions Manual lists 137 ICD-10-CM codes in the logic for DRG 816; 18 of them also map to a CMS-HCC V28 payment category, across 6 categories. The same documentation that supports the inpatient group feeds Medicare Advantage risk adjustment when the patient is an MA enrollee.
| V28 HCC | Category | Shared codes | Examples |
|---|---|---|---|
| HCC 115 | Specified Immunodeficiencies and White Blood Cell Disorders | 8 | D76.1, D76.3, D80.0 |
| HCC 114 | Common Variable and Combined Immunodeficiencies | 5 | D83.0, D83.1, D83.2 |
| HCC 454 | Stem Cell, Including Bone Marrow, Transplant Status/Complications | 2 | Z94.81, Z94.84 |
| HCC 19 | Myelodysplastic Syndromes, Multiple Myeloma, and Other Cancers | 1 | D47.4 |
| HCC 22 | Bladder, Colorectal, and Other Cancers | 1 | D3A.091 |
| HCC 23 | Prostate, Breast, and Other Cancers and Tumors | 1 | D47.3 |
Grouper logic (v44 Definitions Manual)
The manual's split table for Reticuloendothelial and Immunity Disorders gives one row per combination of criteria and the MS-DRG it assigns. DRG 816 is the row where MCC is No, CC is No.
Principal Diagnosis: 137 ICD-10-CM codes in this DRG's assignment logic; the first 12 are shown.
| ICD-10-CM code | Description |
|---|---|
| A18.2 | Tuberculous peripheral lymphadenopathy |
| A18.85 | Tuberculosis of spleen |
| A28.1 | Cat-scratch disease |
| D15.0 | Benign neoplasm of thymus |
| D18.1 | Lymphangioma, any site |
| D36.0 | Benign neoplasm of lymph nodes |
| D3A.091 | Benign carcinoid tumor of the thymus |
| D47.2 | Monoclonal gammopathy |
| D47.3 | Essential (hemorrhagic) thrombocythemia |
| D47.4 | Osteomyelofibrosis |
| D68.312 | Antiphospholipid antibody with hemorrhagic disorder |
| D68.51 | Activated protein C resistance |
Code editor, HAC and CC/MCC exclusion notes for DRG 816
Because this family splits by CC and MCC, a secondary diagnosis on the hospital-acquired condition list that is reported with a present-on-admission indicator of N or U does not count toward the severity level, and a CC or MCC excluded by the principal diagnosis does not count either. Check a secondary diagnosis and its CC exclusion before relying on it for the higher member.
The Definitions Manual lists the diagnosis and procedure codes that lead to DRG 816; these are the ones that are also on a Medicare Code Editor list and can draw that edit.
Documentation and denial exposure
As a medical DRG, assignment depends on the principal diagnosis sequenced from the attending's documentation; a secondary condition sequenced first, or a symptom code in place of the confirmed diagnosis, changes the MDC or the DRG. Because this family splits by severity, auditors target CC and MCC capture: each secondary diagnosis must be documented as present, monitored, evaluated or treated during the stay to survive a DRG-validation review. Typical inpatient denial codes for this group: CARC 16 (claim lacks information needed to group the stay), CARC 50 (the admission or procedure is judged not medically necessary), CARC 97 (a service is bundled into the DRG payment).
For teams evaluating QuickIntell software
Evaluate a documentation and coding workflow for DRG 816
Explore QuickCode for qualified coder review and documentation clarification, or QuickScribe for clinician-reviewed visit documentation. Confirm inpatient scope, the supported grouper version and reviewer responsibilities during evaluation. This public reference is not a production grouper and does not determine a claim's reimbursement.
Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.
Frequently asked questions — DRG 816
What is MS-DRG 816?
MS-DRG 816 is "Reticuloendothelial and Immunity Disorders without CC/MCC", a medical Medicare Severity Diagnosis-Related Group in MDC 16 (Diseases and Disorders of Blood, Blood Forming Organs and Immunologic Disorders). Medicare pays inpatient stays grouped here at the hospital's base rate multiplied by the DRG relative weight.
What is the FY2027 relative weight for DRG 816?
The FY2027 relative weight is 0.7381 (IPPS final rule Table 5, effective October 1, 2026). In FY2026 it was 0.6320, a change of +16.8%.
What is the Medicare base payment for MS-DRG 816?
$5,054.51 for operating costs plus $398.54 for capital, $5,453.05 together, at the FY2027 national rates: weight 0.7381 times the $6,848.00 operating standardized amount and the $539.95 capital rate (IPPS Tables 1A and 1D as corrected by CMS-1849-CN3). DRG 814 (with MCC) comes to $14,195.22 operating on the same basis. DRG 815 (with CC) comes to $7,152.05 operating on the same basis. The hospital's wage index, IME, DSH, outlier and transfer adjustments change what a given stay is paid.
What is the average length of stay for DRG 816?
CMS reports a geometric mean length of stay of 2.1 days and an arithmetic mean of 2.6 days for FY2027. The geometric mean is used for transfer-payment calculations.
Which DRGs are in the same CC/MCC family as 816?
DRG 814 (with MCC, weight 2.0729, GMLOS 4.8 days); DRG 815 (with CC, weight 1.0444, GMLOS 3.0 days). Together with DRG 816 the family spans 0.7381 to 2.0729, a 2.81x spread, so documented complications and comorbidities change payment materially.
What documentation supports the severity level of DRG 816?
DRG 816 is the base-severity assignment: no secondary diagnosis on the CC or MCC lists was coded, or the only ones present are excluded for this principal diagnosis. Revenue-integrity review here looks for undercapture, meaning conditions treated during the stay (electrolyte disorders, specified anemia, acute blood loss, pressure injuries present on admission) that were never documented to the specificity the lists require. A compliant query to the attending, not a coder assumption, is the only way to move a stay to the CC or MCC sibling.
Which codes group to DRG 816?
The v44 Definitions Manual lists 137 principal diagnosis codes for this group. Examples from the principal diagnosis list, D18.1 (Lymphangioma, any site); D36.0 (Benign neoplasm of lymph nodes); D3A.091 (Benign carcinoid tumor of the thymus); D47.2 (Monoclonal gammopathy).
Is DRG 816 a post-acute transfer DRG?
No. DRG 816 is not on the FY2027 post-acute care transfer list, so the transfer per-diem policy does not apply to it.
Sources
Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.
- IPPS FY2027 Table 5 as corrected by correction notice CMS-1849-CN3Version v44 FY2027 (final rule + CN3) · effective 2026-10-01 · file CMS-1849-CN Table 5.txtSHA-256 2cc4e0b083e62e40…
- IPPS FY2026 Final Rule Table 5 (CMS-1833-F)Version v43 FY2026 · effective 2025-10-01 · file CMS-1833-F Table 5.txtSHA-256 bf8c390d14b3cd3e…
- ICD-10 MS-DRG Definitions Manual v44 (text)Version v44 · effective 2026-10-01 · file fy2027-fr-icd10-ms-drg-definitions-manual-files-v44.zipSHA-256 ae4f6c11727fe91f…
Disclaimer
This page is an operational reference compiled from the CMS IPPS FY2027 final rule (Table 5) and the v44 ICD-10 MS-DRG Definitions Manual. Relative weights are national factors; actual payment depends on each hospital's wage-adjusted base rate, add-ons, outliers and transfer adjustments. Nothing here is legal, clinical or billing advice; verify grouping against your encoder and the published CMS files.
Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.